A multiparameter flow cytometric analysis of the effect of bexarotene on the epidermis of the psoriatic lesion

British Journal of Dermatology

Volumn 149, Issue 3, 2003, Pages 506-512

  Franssen, M E J ^a   Smit, J V ^a   Van Erp, P E J ^a   Van De Kerkhof, P C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bexarotene; Cell proliferation; Keratinization; Psoriasis; Retinoid X receptor

Indexed keywords

BEXAROTENE; KERATIN; KERATIN 10; KERATIN 6; RETINOID X RECEPTOR; THERMOLYSIN; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SIZE; CELL SUSPENSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DNA CONTENT; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EPIDERMIS CELL; ERYTHEMA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; KERATINIZATION; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS VULGARIS; PUNCH BIOPSY; SKIN BIOPSY; SKIN DEFECT; SKIN EXFOLIATION; SKIN INDURATION; TREATMENT OUTCOME;

ADULT; AGED; CELL DIFFERENTIATION; CELL DIVISION; DERMATOLOGIC AGENTS; EPIDERMIS; FEMALE; FLOW CYTOMETRY; HUMANS; KERATINOCYTES; MALE; MIDDLE AGED; PSORIASIS; TETRAHYDRONAPHTHALENES; VIMENTIN;

EID: 0142088943     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2003.05474.x     Document Type: Article

References (28)

1. Chandraratna RA. Rational design of receptor-selective retinoids. J Am Acad Dermatol 1998; 39: S124-8.
2. Orfanos CE, Zouboulis CC, Almond-Roesler B et al. Current use and future potential role of retinoids in dermatology. Drugs 1997; 53: 358-88.
3. Carlberg C, Saurat JH. Vitamin D-retinoid association: molecular basis and clinical applications. J Invest Dermatol Symp Proc 1996; 1: 82-6.
4. Miller VA, Benedetti FM, Rigas JR et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997; 15: 790-5.
5. Rizvi NA, Marshall JL, Dahut W et al. A phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res 1999; 5: 1658-64.
6. Bedikian AY, Plager C, Papadopoulos N et al. A phase II evaluation of bexarotene (Targretin) capsules in patients with metastatic melanoma. Oncol Rep 2000; 7: 883-6.
7. Bischoff ED, Gottardis MM, Moon TE et al. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 1998; 58: 479-84.
8. Smit JV, de Jong EM, van Hooijdonk CA, van de Kerkhof PC. Systemic bexarotene (Targretin, Ligand Pharmaceuticals Inc.) significantly inhibits proliferation and inflammation and improves normal differentiation in moderate to severe plaque psoriasis: an immunohistochemical study. Br J Dermatol 1999; 141: 992-3.
9. Smit JV, de Jong EM, van Hooijdonk CA et al. A multicentre phase 2 clinical and immunohistochemical trial of systemic bexarotene (Targretin) in psoriasis. J Invest Dermatol 2000; 114: 776 (Abstr.).
10. van Erp PE, Rijzewijk JJ, Boezeman JB et al. Flow cytometric analysis of epidermal subpopulations from normal and psoriatic skin using monoclonal antibodies against intermediate filaments, Am J Pathol 1989; 135: 865-70.
11. Glade CP, van Erp PE, Boezeman JB et al. Multiparameter flow cytometry as a tool to evaluate antipsoriatic therapy. Br J Dermatol 1997; 137: 367-75.
12. Mortimers JM, Goossen JW, van de Kerkhof PC et al. Novel functional multiparameter flow cytometric assay to characterize proliferation in skin. Cytometry 2000; 42: 43-9.
13. Glade CP, Seegers BA, Meulen EF et al. Multiparameter flow cytometric characterization of epidermal cell suspensions prepared from normal and hyperproliferative human skin using an optimized thermolysin-trypsin protocol. Arch Dermatol Res 1996; 288: 203-10.
14. Glade CP, van Erp PE, van Hooijdonk CA et al. Topical treatment of psoriatic plaques with 1 alpha, 24 dihydroxyvitamin D3: a multiparameter flow cytometrical analysis of epidermal growth, differentiation and inflammation. Acta Derm Venereol 1995; 75: 381-5.
15. Glade CP, van Erp PE, van de Kerkhof PC. Epidermal cell DNA content and intermediate filaments keratin 10 and vimentin after treatment of psoriasis with calcipotriol cream once daily, twice daily and in combination with clobetasone 17-butyrate cream or betamethasone 17-valerate cream: a comparative flow cytometric study. Br J Dermatol 1996; 135: 379-84.
16. Glade CP, van Erp PE, Werner-Schlenzka H et al. A clinical and flow cytometric model to study remission and relapse in psoriasis. Acta Derm Venereol 1998; 78: 180-5.
17. Mommers JM, van Erp PE, van de Kerkhof PC. Clobetasol under hydrocolloid occlusion in psoriasis results in a complete block of proliferation and in a rebound of lesions following discontinuation. Dermatology 1999; 199: 323-7.
18. Mommers JM, van Rossum MM, van Erp PE et al. Changes in keratin 6 and keratin 10 (co-) expression in lesional and symptomless skin of spreading psoriasis. Dermatology 2000; 201: 15-20.
19. Franssen ME, Mommers JM, Cloin WA et al. Monitoring psoriasis: an improved flow cytometric assay. J Invest Dermatol 2000; 115: 582 (Abstr.).
20. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
21. Bauer FW, Boezeman JB. Flow cytometric methods in human skin with respect to cell cycle kinetics. In: Psoriasis: Cell Proliferation (Camplejohn RS, Wright N, eds). Edinburgh: Churchill Livingstone, 1983; 104-16.
22. Agarwal VR, Bischoff ED, Hermann T et al. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin). Cancer Res 2000; 60: 6033-8.
23. Gamage SD, Bischoff ED, Burroughs KD et al. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma. J Pharmacol Exp Ther 2000; 295: 677-81.
24. Hewson QC, Lova PE, Malcolm AJ et al. Receptor mechanisms mediating differentiation and proliferation effects of retinoids on neuroblastoma cells. Neurosci Lett 2000; 279: 113-16.
25. Sheikh MS, Shao ZM, Li XS et al. Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids. J Biol Chem 1994; 269: 21440-7.
26. Gottardis MM, Bischoff ED, Shirley MA et al. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996; 56: 5566-70.
27. de Jong EM, Ferrier CM, de Zwart A et al. Effects of topical treatment with budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis. J Dermatol Sci 1995; 9: 185-94.
28. de Mare S, de Jong EG, van de Kerkhof PC. DNA content and Ks8 12 binding of the psoriatic lesion during treatment with the vitamin D3 analogue MC903 and betamethasone. Br J Dermatol 1990; 123: 291-5.